e-learning
resources
Stockholm 2007
Sunday 16.09.2007
Different aspects of COPD exacerbations
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Which patients with COPD can potentially benefit from prophylactic use of antibiotics?
A. T. Lo Tam Loi, G. I. Andriesse, R. S. Djamin (Breda, Netherlands)
Source:
Annual Congress 2007 - Different aspects of COPD exacerbations
Session:
Different aspects of COPD exacerbations
Session type:
Electronic Poster Discussion
Number:
1384
Disease area:
Airway diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. T. Lo Tam Loi, G. I. Andriesse, R. S. Djamin (Breda, Netherlands). Which patients with COPD can potentially benefit from prophylactic use of antibiotics?. Eur Respir J 2007; 30: Suppl. 51, 1384
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD?
Source: Eur Respir J, 54 (4) 1901597; 10.1183/13993003.01597-2019
Year: 2019
Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD?
Source: Eur Respir J, 54 (4) 1901405; 10.1183/13993003.01405-2019
Year: 2019
Can we use a biomarker to guide antibiotic treatment in severe COPD exacerbations?
Source: Breathe, 15 (4) 353; 10.1183/20734735.0257-2019
Year: 2019
How often do asthma patients claim prescribed therapy?
Source: International Congress 2017 – Asthma from childhood to adulthood and ACOS
Year: 2017
Should we change our antibiotic strategy in AECOPD or CAP+COPD patients?
Source: International Congress 2015 – Differentiating COPD exacerbations from pneumonia in COPD patients
Year: 2015
A digital therapy for proactively managing exacerbations and delivering therapeutic benefit to patients with moderate to severe asthma
Source: International Congress 2019 – Clinical approach to asthma management
Year: 2019
Identifying patients with severe asthma that will be benefit from biological therapy
Source: Virtual Congress 2020 – Rethinking asthma
Year: 2020
Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy?
Source: Eur Respir J 2001; 18: Suppl. 33, 24s
Year: 2001
Who should receive which biologic and why? Current and future approaches in severe asthma patients
Source: Virtual Congress 2021 – Linking scientific mechanisms to recent clinical therapeutic advances in airway disease: why, who, when and what?
Year: 2021
What is the role of prophylactic antibiotic therapy in chronic bronchitis or COPD?
Source: Annual Congress 2009 - PG1 EU GRACE Network Full-day Course: vaccination and preventive measures for LRTIs in the community: what’s new?
Year: 2009
Should severe CAP patients receive anti-MRSA coverage? Pro argument
Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate
Year: 2017
Two therapy option in patients with uncontrolled asthma
Source: International Congress 2018 – Physiological and biological insights in asthma
Year: 2018
Does azithromycin-prednisolone combination therapy have additive effects than single therapy in patients with persistent asthma?
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009
De-implementing inappropriate inhaled steroids use in Dutch COPD patients in primary care
Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD
Year: 2019
Cost consequences of tiotropium plus existing therapy
versus
existing therapy alone following one year of treatment in patients with COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 5s
Year: 2001
Do cardiovascular drugs reduce exacerbations rates in primary care patients with COPD?
Source: Eur Respir J 2007; 30: Suppl. 51, 126s
Year: 2007
Do empiric antibiotics delay appropriate antituberculosis medication in patients with active pulmonary tuberculosis?
Source: Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis
Year: 2008
Current approaches to the prevention of tuberculosis in patients receiving immunosuppressants
Source: Virtual Congress 2021 – Epidemiological aspects of tuberculosis
Year: 2021
Does long-term macrolide treatment reduce asthma exacerbations? An individual patient data meta-analysis
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019
Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study
Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept